Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management

S J E Hwang; R Anforth; G Carlos; P Fernandez-Peñas

doi:10.1016/j.ad.2016.05.019

Cutaneous Adverse Events of New Anti-melanoma Therapies: Classification and Management

Actas Dermosifiliogr. 2017 Jan-Feb;108(1):6-16. doi: 10.1016/j.ad.2016.05.019. Epub 2016 Sep 15.

[Article in English, Spanish]

Authors

S J E Hwang¹, R Anforth², G Carlos², P Fernandez-Peñas²

Affiliations

¹ Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia. Electronic address: shelley.hwang@hotmail.com.
² Department of Dermatology, Westmead Hospital, Westmead, NSW, Australia; Sydney Medical School, The University of Sydney, Sydney, NSW, Australia.

PMID: 27642030
DOI: 10.1016/j.ad.2016.05.019

Abstract

Over the past decade, targeted therapies such as BRAF inhibitors, MEK inhibitors and immunotherapies such as anti-CTLA4 and anti-PD1 antibodies have emerged as novel treatments of advanced melanoma. Along with increased use of these therapies, a range of cutaneous adverse events have also emerged, varying from more serious and frequent cutaneous squamous cell carcinoma to mere cosmetic changes such as curly hair or rare severe toxic epidermal necrolysis. Early detection and management of these cutaneous adverse events will aid patients to receive accurate treatment, avoid unnecessary discontinuation of anti-tumour treatment and improve the patient's overall quality of life. This review will describe various cutaneous adverse events of anti-melanoma therapies and its management.

Keywords: Anti-CTLA4; Anti-Cytotoxic T-lymphocyte-associated protein 4; Anti-PD1; Anti-Programmed cell death-1; B-Raf inhibitors; Cutaneous adverse event; Efecto cutáneo adverso; Inhibidores de BRAF; Inhibidores de MEK; Melanoma metastásico; Metastatic melanoma; Mitogen-activated protein kinase inhibitor.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / adverse effects
Antibodies, Monoclonal / therapeutic use
Antineoplastic Agents / adverse effects*
Antineoplastic Agents / therapeutic use
CTLA-4 Antigen / antagonists & inhibitors
Carcinoma, Squamous Cell / chemically induced
Drug Eruptions / classification
Drug Eruptions / etiology*
Drug Eruptions / therapy
Drug Synergism
Hair Diseases / chemically induced
Humans
Keratosis / chemically induced
Melanoma / drug therapy*
Molecular Targeted Therapy / adverse effects*
Neoplasm Proteins / antagonists & inhibitors
Neoplasms, Second Primary / chemically induced
Panniculitis / chemically induced
Photosensitivity Disorders / chemically induced
Programmed Cell Death 1 Receptor / antagonists & inhibitors
Protein Kinase Inhibitors / adverse effects
Protein Kinase Inhibitors / therapeutic use
Quality of Life
Skin Neoplasms / chemically induced
Skin Neoplasms / drug therapy*
Vitiligo / chemically induced

Substances

Antibodies, Monoclonal
Antineoplastic Agents
CTLA-4 Antigen
CTLA4 protein, human
Neoplasm Proteins
PDCD1 protein, human
Programmed Cell Death 1 Receptor
Protein Kinase Inhibitors